Johnson & Johnson seeks US FDA approval for icotrokinra to treat paediatric patients 12 years of age and older with ...
Johnson & Johnson announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking the first approval of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 …